Investors Say Teva Can't Get Early Win in Price-Fixing Suit
Investors guided by Highfields Capital told a Connecticut federal court that Teva Pharmaceuticals can't escape their claims that its alleged collusion with other drugmakers to artificially inflate the price of generic...To view the full article, register now.
Already a subscriber? Click here to view full article